GREY:ICOTF - Post by User
Post by
stockgurukingon Nov 13, 2012 1:57pm
254 Views
Post# 20594360
Interim Phase II Data Pending...
Interim Phase II Data Pending... Based on the trial's official website (www.idealstudy.org) they will have full enrollment by the end of the year, this means that they very likely have a substantial number of patients enrolled already with the required 8 month follow up completed. Meaning Interim Data is weeks away. Looking back at the recent deals in the ophthalmic space tells me that mid and big Pharma is willing to pull the trigger on promising "early" data.
*
Many of you have already heard that iCo's partner, on a secondary asset (ICO-008), Immune Pharmaceuticals, has been planning a listing on a major US exchange and in conjunction with that a large raise ($20-30MM). Well, last week Immune announced a definitive agremeement to list on the NASDAQ via a RTO. The next step is raising the cash - which based on their engagement of ROTH Capital shouldn't be a problem. ROTH has been an absolute power house in the Health Care space over the past couple of years. Post RTO and without even raising the cash ICO's 6% ownership of Immune will be worth a minimum of $2MM.